News
More NewsDietary habits of individuals living with PSC - ERN RARE-LIVER Survey for Patients
This research is designed to explore how individuals adapt their diets due to PSC, and if applicable, due to underlying Inflammatory Bowel Disease (IBD). Additionally, we seek to identify the primary sources of information individuals with PSC rely on for dietary advice.
ERN RARE-LIVER Wilson Disease and Pregnancy Survey - for Physicians
Please collaborate with the European ERN RARE-LIVER Wilson Group by answering this anonymous survey on pregnancy and contraception for Wilson Disease Women. Thank you for your collaboration!
ERN RARE-LIVER Wilson Disease and Pregnancy Survey - for Patients
Please collaborate with the European ERN RARE-LIVER Wilson Group by answering this anonymous survey on pregnancy and contraception for Wilson Disease Women.
Thank you for your collaboration!
Ocaliva marketing authorisation was finally revoked by the European Medicines Agency (EMA)
The marketing authorisation for Ocaliva was finally revoked by the European Medicines Agencys (EMA) after the EMA had already recommended revoking Ocaliva’s marketing authorization in June 2024. It says the benefits of Ocaliva are no longer considered to outweigh its risks
ERN RARE-LIVER Transition of healthcare template
This ERN RARE-LIVER template aims to improve the communication and information transfer from paediatric services to the adult department, facilitating a smoother transition of care for patients.
ERN RARE-LIVER Study - Survey for people with PSC, PBC or AIH
Social determinants of health (SDOH) are the conditions in which people are born, grow up, work and age. Studies suggest that SDOH influence the course of liver disease. However, this has not yet been studied in patients with autoimmune liver disease.
ERN RARE-LIVER Members' Meeting 23 + 24 January 2025
Save the date for our Members’ Meeting in Barcelona on 23 + 24 January 2025.
Participation is limited to two representatives per member centre, including affiliated partners. One of the participants can be funded per centre, according to EC regulations (EU unit costs).
EASL Academy 2025
The ERN RARE-LIVER EASL ACADEMY 2025 will be hosted by the university hospital of Heidelberg and will focus on rare liver diseases with special focus on translating clinical practice guidelines in real-life care.
Tips how to take medication regularly
These tips are a team effort by Aida Regi Cosculluela and Dr Wiebke Papenthin,
named patient representatives of the ERN RARE-LIVER Wilson working group and the ERN Youth Panel.
Scientific News
More Scientific NewsERN Paper in Gastroenterology - Longitudinal Evaluation of Individuals With Severe AATD
Non-invasive liver fibrosis surrogates are superior to lung parameter for prediction of organ-related outcomes. Liver disease progresses primarily in those individuals with risk factors/signs of liver injury.
ERN RARE-LIVER/EASL Position Paper on Rare primary liver cancers
In this position paper, an international panel of experts representing oncology, hepatology, pathology, radiology, surgery, and molecular biology has summarised the available information and evidence on the pathogenesis, diagnosis, and treatment of rare PLCs.
New ERN RARE-LIVER Paper on PSVD - Journal of Hepatology
Porto-sinusoidal vascular liver disorder (PSVD) is a rare liver condition that often leads to severe complications from portal hypertension and can reduce life expectancy.
For Physicians: New ERN RARE-LIVER Survey on Alcohol Use
ERN RARE-LIVER has constructed the survey “Counselling Young Adults With Liver Disease On Alcohol Use”. The survey will be open until 8 September, 2024. It consists of max. 10 pages and it will take 10 to 15 minutes to respond.
Open letter to the European Commision
The rare disease community comes together in calling on the EU institutions and our national governments to stand by the European Reference Networks.
COST ACTION EURO-VALDI-NET accepted
Congratulations to Pierre-Emmanuel Rautou and colleagues for their successful COST Action application! 134 researchers from 27 countries put together the EURO-VALDI-NET project on vascular liver diseases.